Article
Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments
17 May 2022
Abstract excerpt
Doravirine is currently not recommended for pregnant women living with human immunodeficiency virus because efficacy and safety data are lacking. This study aimed to predict maternal and fetal doravirine exposure by integrating human placenta perfusion experiments with pregnancy physiologically based pharmacokinetic (PBPK) modeling. Ex vivo placenta perfusions were performed in a closed–closed configuration, in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
